|
|
| |
| Articles
by
Kent J. Weinhold |
Total Records (
3 ) for
Kent J. Weinhold |
|
 |
| |
|
| |
S. Munir Alam
,
Richard M. Scearce
,
Robert J. Parks
,
Kelly Plonk
,
Steven G. Plonk
,
Laura L. Sutherland
,
Miroslaw K. Gorny
,
Susan Zolla-Pazner
,
Stacie VanLeeuwen
,
M. Anthony Moody
,
Shi-Mao Xia
,
David C. Montefiori
,
Georgia D. Tomaras
,
Kent J. Weinhold
,
Salim Abdool Karim
,
Charles B. Hicks
,
Hua-Xin Liao
,
James Robinson
,
George M. Shaw
and
Barton F. Haynes
|
| |
Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency virus type 1 (HIV-1) envelope g41 cluster II membrane proximal external region (MPER) broadly neutralize HIV-1 primary isolates. However, these antibody specificities are rare, are not induced by Env immunization or HIV-1 infection, and are polyspecific and also react with lipids such as cardiolipin or phosphatidylserine. To probe MPER anti-gp41 antibodies that are produced in HIV-1 infection, we have made two novel murine MAbs, 5A9 and 13H11, against HIV-1 gp41 envelope that partially cross-blocked 2F5 MAb binding to Env but did not neutralize HIV-1 primary isolates or bind host lipids. Competitive inhibition assays using labeled 13H11 MAb and HIV-1-positive patient plasma samples demonstrated that cluster II 13H11-blocking plasma antibodies were made in 83% of chronically HIV-1 infected patients and were acquired between 5 to 10 weeks after acute HIV-1 infection. Both the mouse 13H11 MAb and the three prototypic cluster II human MAbs (98-6, 126-6, and 167-D) blocked 2F5 binding to gp41 epitopes to variable degrees; the combination of 98-6 and 13H11 completely blocked 2F5 binding. These data provide support for the hypothesis that in some patients, B cells make nonneutralizing cluster II antibodies that may mask or otherwise down-modulate B-cell responses to immunogenic regions of gp41 that could be recognized by B cells capable of producing antibodies like 2F5. |
|
| |
|
| |
Nancy Gasper-Smith
,
Deanna M. Crossman
,
John F. Whitesides
,
Nadia Mensali
,
Janet S. Ottinger
,
Steven G. Plonk
,
M. Anthony Moody
,
Guido Ferrari
,
Kent J. Weinhold
,
Sara E. Miller
,
Charles F. Reich
,
Li Qin
,
Stephen G. Self
,
George M. Shaw
,
Thomas N. Denny
,
Laura E. Jones
,
David S. Pisetsky
and
Barton F. Haynes
|
| |
The death of CD4+ CCR5+ T cells is a hallmark of human immunodeficiency virus (HIV) infection. We studied the plasma levels of cell death mediators and products—tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), Fas ligand, TNF receptor type 2 (TNFR-2), and plasma microparticles—during the earliest stages of infection following HIV type 1 (HIV-1) transmission in plasma samples from U.S. plasma donors. Significant plasma TRAIL level elevations occurred a mean of 7.2 days before the peak of plasma viral load (VL), while TNFR-2, Fas ligand, and microparticle level elevations occurred concurrently with maximum VL. Microparticles had been previously shown to mediate immunosuppressive effects on T cells and macrophages. We found that T-cell apoptotic microparticles also potently suppressed in vitro immunoglobulin G (IgG) and IgA antibody production by memory B cells. Thus, release of TRAIL during the onset of plasma viremia (i.e., the eclipse phase) in HIV-1 transmission may initiate or amplify early HIV-1-induced cell death. The window of opportunity for a HIV-1 vaccine is from the time of HIV-1 transmission until establishment of the latently infected CD4+ T cells. Release of products of cell death and subsequent immunosuppression following HIV-1 transmission could potentially narrow the window of opportunity during which a vaccine is able to extinguish HIV-1 infection and could place severe constraints on the amount of time available for the immune system to respond to the transmitted virus. |
|
| |
|
| |
Georgia D. Tomaras
,
Nicole L. Yates
,
Pinghuang Liu
,
Li Qin
,
Genevieve G. Fouda
,
Leslie L. Chavez
,
Allan C. Decamp
,
Robert J. Parks
,
Vicki C. Ashley
,
Judith T. Lucas
,
Myron Cohen
,
Joseph Eron
,
Charles B. Hicks
,
Hua- Xin Liao
,
Steven G. Self
,
Gary Landucci
,
Donald N. Forthal
,
Kent J. Weinhold
,
Brandon F. Keele
,
Brandon F. Keele
,
Michael L. Greenberg
,
Lynn Morris
,
Salim S. Abdool Karim
,
William A. Blattner
,
David C. Montefiori
,
George M. Shaw
,
Alan S. Perelson
and
Barton F. Haynes
|
| |
A window of opportunity for immune responses to extinguish human immunodeficiency virus type 1 (HIV-1) exists from the moment of transmission through establishment of the latent pool of HIV-1-infected cells. A critical time to study the initial immune responses to the transmitted/founder virus is the eclipse phase of HIV-1 infection (time from transmission to the first appearance of plasma virus), but, to date, this period has been logistically difficult to analyze. To probe B-cell responses immediately following HIV-1 transmission, we have determined envelope-specific antibody responses to autologous and consensus Envs in plasma donors from the United States for whom frequent plasma samples were available at time points immediately before, during, and after HIV-1 plasma viral load (VL) ramp-up in acute infection, and we have modeled the antibody effect on the kinetics of plasma viremia. The first detectable B-cell response was in the form of immune complexes 8 days after plasma virus detection, whereas the first free plasma anti-HIV-1 antibody was to gp41 and appeared 13 days after the appearance of plasma virus. In contrast, envelope gp120-specific antibodies were delayed an additional 14 days. Mathematical modeling of the earliest viral dynamics was performed to determine the impact of antibody on HIV replication in vivo as assessed by plasma VL. Including the initial anti-gp41 immunoglobulin G (IgG), IgM, or both responses in the model did not significantly impact the early dynamics of plasma VL. These results demonstrate that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection. |
|
|
|
|
| |
|